Hans Lee MD

Hematologic Oncology

Physician

335 24th Ave NSte 200Nashville, TN 37203
Phone+1 615-284-2310

Dr. Lee is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lee's full profile Already have an account?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2008 - 2011
Indiana University School of MedicineClass of 2008

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2012 - 2028
GA State Medical License 2022 - 2027
MS State Medical License 2022 - 2027
TN State Medical License 2022 - 2027
AL State Medical License 2022 - 2026
AZ State Medical License 2022 - 2026
LA State Medical License 2022 - 2026
OK State Medical License 2020 - 2026
NM State Medical License 2021 - 2025
WA State Medical License 2022 - 2025
MO State Medical License 2010 - 2012
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Join now to see all

Clinical Trials

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
COMPLETED
PHASE2
Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis Start of enrollment: 2018 Feb 07
COMPLETED
PHASE1
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2019 Jan 23
RECRUITING
PHASE1, PHASE2
Roles: Contact

Publications & Presentations

PubMed

Health-related quality of life with linvoseltamab treatment for relapsed/refractory multiple myeloma in LINKER-MM1.
James E Hoffman, Naresh Bumma, Joshua Richter, Madhav V Dhodapkar, Hans C Lee
Blood Neoplasia. 2026-08-01
Prognostic impact of monosomy 13 and deletion of 13q in multiple myeloma patients undergoing upfront autologous transplantation.
Damian M Mikulski, Curtis Marcoux, Mark R Tanner, Qaiser Bashir, Samer Srour
British Journal of Haematology. 2026-07-24
Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.
Joshua Richter, Hans C Lee, Sundar Jagannath, Jeffrey A Zonder, James E Hoffman
Leukemia & Lymphoma. 2026-07-10

Journal Articles

Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs
Krina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191
Sheeba K Thomas, Robert Z Orlowski, Hans C Lee, Clinical Cancer Research

Abstracts/Posters

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
Hans C. Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
Hans C. Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
Hans C. Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

A 3D Learning Experience: Novel Combination Treatment Options and Sequencing Strategies for Personalized Management of Relapsed and/or Refractory Multiple Myeloma
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Treatment Patterns and Outcomes in Elderly Patients with Newly Diagnosed Multiple Myeloma: Results from the Connect¬ MM Registry
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Blood Cancer Awareness: Early Detection and Clinical Trials Improve Treatment OptionsSeptember 15th, 2025
New Drugs Target Cancer CellsJuly 4th, 2022
Foundation Awards $4.45M to More Than 50 Leading Investigators to Support Promising Research CareersSeptember 12th, 2018